Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
Introduction - Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2024
|
| In: |
European journal of cancer
Year: 2024, Volume: 208, Pages: 1-11 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2024.114229 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2024.114229 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804924008852 
|
| Author Notes: | Xavier Choderlos de Laclos, Séverine Risbourg, Bernadette Brennan, François Bertucci, Nathalie Gaspar, Hans Gelderblom, Douglas S. Hawkins, Katherine Janeway, Heribert Juergens, Bernd Kasper, Mark D. Krailo, Marie Cécile Le Deley, Perrine Marec-Bérard, Martin G. McCabe, Markus Metzler, Andreas Ranft, Sandra Strauss, Marie-Dominique Tabone, Rachael Windsor, Uta Dirksen, Virginie Gandemer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1908403020 | ||
| 003 | DE-627 | ||
| 005 | 20260224120524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241113s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.114229 |2 doi | |
| 035 | |a (DE-627)1908403020 | ||
| 035 | |a (DE-599)KXP1908403020 | ||
| 035 | |a (OCoLC)1475647399 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Choderlos de Laclos, Xavier |e VerfasserIn |0 (DE-588)1348171685 |0 (DE-627)1908404272 |4 aut | |
| 245 | 1 | 0 | |a Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials |c Xavier Choderlos de Laclos, Séverine Risbourg, Bernadette Brennan, François Bertucci, Nathalie Gaspar, Hans Gelderblom, Douglas S. Hawkins, Katherine Janeway, Heribert Juergens, Bernd Kasper, Mark D. Krailo, Marie Cécile Le Deley, Perrine Marec-Bérard, Martin G. McCabe, Markus Metzler, Andreas Ranft, Sandra Strauss, Marie-Dominique Tabone, Rachael Windsor, Uta Dirksen, Virginie Gandemer |
| 264 | 1 | |c September 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 15. Juli 2024, Artikelversion: 19. Juli 2024 | ||
| 500 | |a Gesehen am 13.11.2024 | ||
| 520 | |a Introduction - Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved outcomes in unfavourable localized ES, but with more toxicities than conventional chemotherapy (VAI: Vincristine-dactinomycin-Ifosfamide). We evaluated whether the risk of acute toxicity associated with BuMel compared to VAI varied according to age in patients recruited in the R2Loc and R2Pulm randomised trials of the Euro-E.W.I.N.G.99 and Ewing-2008 trials. - Methods - We included patients with a localized high-risk disease, or pulmonary or pleural metastasis. We analysed the risk of severe toxicity according to randomised treatment group (VAI versus BuMel) and age group (<12 years, 12-17 years, 18-24 years, ≥25 years). We evaluated the heterogeneity of treatment effects by age group using interaction terms in logistic multivariable models. - Results - The analysis included 243 patients treated with VAI and 205 with BuMel. Overall, BuMel was associated with a higher risk of severe acute toxicity than VAI particularly haematological, gastrointestinal, liver, sinusoidal occlusive syndrome, and infections. Severe haematological toxicity and lower general condition were significantly more frequent in younger patients, whatever treatment. We did not observe any significant heterogeneity in terms of the excess risk of severe toxicities associated with BuMel compared to VAI according to age group. - Conclusion - The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups. | ||
| 650 | 4 | |a Autologous hematopoietic stem cells transplantation | |
| 650 | 4 | |a Ewing sarcoma (ES) | |
| 650 | 4 | |a High dose chemotherapy | |
| 650 | 4 | |a Safety | |
| 700 | 1 | |a Risbourg, Séverine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brennan, Bernadette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bertucci, François |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gaspar, Nathalie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gelderblom, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hawkins, Douglas S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janeway, Katherine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Juergens, Heribert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kasper, Bernd |d 1974- |e VerfasserIn |0 (DE-588)12274764X |0 (DE-627)082130736 |0 (DE-576)29340447X |4 aut | |
| 700 | 1 | |a Krailo, Mark D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cécile Le Deley, Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marec-Bérard, Perrine |e VerfasserIn |4 aut | |
| 700 | 1 | |a McCabe, Martin G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Metzler, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ranft, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Strauss, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tabone, Marie-Dominique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Windsor, Rachael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dirksen, Uta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gandemer, Virginie |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 208(2024) vom: Sept., Artikel-ID 114229, Seite 1-11 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials |
| 773 | 1 | 8 | |g volume:208 |g year:2024 |g month:09 |g elocationid:114229 |g pages:1-11 |g extent:11 |a Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2024.114229 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804924008852 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20241113 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 12274764X |a Kasper, Bernd |m 12274764X:Kasper, Bernd |d 60000 |d 61200 |e 60000PK12274764X |e 61200PK12274764X |k 0/60000/ |k 1/60000/61200/ |p 10 | ||
| 999 | |a KXP-PPN1908403020 |e 4613781809 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Choderlos de Laclos, Xavier","family":"Choderlos de Laclos","role":"aut","given":"Xavier"},{"role":"aut","given":"Séverine","display":"Risbourg, Séverine","family":"Risbourg"},{"family":"Brennan","display":"Brennan, Bernadette","given":"Bernadette","role":"aut"},{"family":"Bertucci","display":"Bertucci, François","given":"François","role":"aut"},{"family":"Gaspar","display":"Gaspar, Nathalie","given":"Nathalie","role":"aut"},{"display":"Gelderblom, Hans","family":"Gelderblom","role":"aut","given":"Hans"},{"display":"Hawkins, Douglas S.","family":"Hawkins","role":"aut","given":"Douglas S."},{"display":"Janeway, Katherine","family":"Janeway","role":"aut","given":"Katherine"},{"family":"Juergens","display":"Juergens, Heribert","given":"Heribert","role":"aut"},{"given":"Bernd","role":"aut","family":"Kasper","display":"Kasper, Bernd"},{"role":"aut","given":"Mark D.","display":"Krailo, Mark D.","family":"Krailo"},{"family":"Cécile Le Deley","display":"Cécile Le Deley, Marie","given":"Marie","role":"aut"},{"given":"Perrine","role":"aut","family":"Marec-Bérard","display":"Marec-Bérard, Perrine"},{"role":"aut","given":"Martin G.","display":"McCabe, Martin G.","family":"McCabe"},{"display":"Metzler, Markus","family":"Metzler","role":"aut","given":"Markus"},{"given":"Andreas","role":"aut","family":"Ranft","display":"Ranft, Andreas"},{"given":"Sandra","role":"aut","family":"Strauss","display":"Strauss, Sandra"},{"role":"aut","given":"Marie-Dominique","display":"Tabone, Marie-Dominique","family":"Tabone"},{"family":"Windsor","display":"Windsor, Rachael","given":"Rachael","role":"aut"},{"role":"aut","given":"Uta","display":"Dirksen, Uta","family":"Dirksen"},{"display":"Gandemer, Virginie","family":"Gandemer","role":"aut","given":"Virginie"}],"title":[{"title":"Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials","title_sort":"Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials"}],"note":["Online verfügbar: 15. Juli 2024, Artikelversion: 19. Juli 2024","Gesehen am 13.11.2024"],"language":["eng"],"relHost":[{"pubHistory":["28.1992 -"],"recId":"266883400","title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"language":["eng"],"disp":"Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trialsEuropean journal of cancer","titleAlt":[{"title":"EJC online"}],"part":{"year":"2024","extent":"11","pages":"1-11","text":"208(2024) vom: Sept., Artikel-ID 114229, Seite 1-11","volume":"208"},"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["1468190-0"],"eki":["266883400"],"issn":["1879-0852"]},"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology"}],"origin":[{"dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}]}],"recId":"1908403020","origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"September 2024"}],"id":{"doi":["10.1016/j.ejca.2024.114229"],"eki":["1908403020"]},"name":{"displayForm":["Xavier Choderlos de Laclos, Séverine Risbourg, Bernadette Brennan, François Bertucci, Nathalie Gaspar, Hans Gelderblom, Douglas S. Hawkins, Katherine Janeway, Heribert Juergens, Bernd Kasper, Mark D. Krailo, Marie Cécile Le Deley, Perrine Marec-Bérard, Martin G. McCabe, Markus Metzler, Andreas Ranft, Sandra Strauss, Marie-Dominique Tabone, Rachael Windsor, Uta Dirksen, Virginie Gandemer"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"11 S."}]} | ||
| SRT | |a CHODERLOSDIMPACTOFAG2024 | ||